Federal Criminal Defense for Compounding Pharmacy TRICARE Fraud: 18 U.S.C. § 287
Compounding pharmacies that bill TRICARE, the federal health care program for active-duty military, veterans, and their families, are at the center of one of the most aggressively prosecuted categories of fraud under federal law.
The Department of Justice, Defense Criminal Investigative Service (DCIS), FBI, and HHS-OIG have coordinated for over a decade to pursue compounding pharmacy operators, owners, and affiliated marketers under 18 U.S.C. § 287, the federal false claims statute.
The sentences handed down in these cases are not administrative penalties.
They are measured in years of federal imprisonment, millions in forfeiture, and permanent exclusion from every federal health program.
A compounding pharmacy targeted for TRICARE fraud does not have the luxury of time.
Federal investigations in this space are typically well-developed before any contact is made with the target. Counsel must be in place before a single statement is given, and ideally before a grand jury subpoena arrives.
What 18 U.S.C. § 287 Prohibits
Section 287 of Title 18 provides that whoever makes or presents to any person or officer in the civil, military, or naval service of the United States, or to any department or agency thereof, any claim against the United States knowing such claim to be false, fictitious, or fraudulent, shall be imprisoned not more than five years and shall be subject to a fine.
The statute is deceptively short. Applied to compounding pharmacy billing, it serves as the criminal backbone of a broader prosecutorial framework.
A conviction for false claims can result in up to five years in federal prison per count, along with fines, restitution, and additional penalties depending on the amount of loss and the number of claims submitted.
In false claims cases, federal sentencing is heavily influenced by the loss amount, which is the value of the claims submitted to the government.
In a compounding pharmacy case billing TRICARE at several thousand dollars per prescription, even a few months of volume can generate loss figures that trigger significant sentencing enhancements under the U.S. Sentencing Guidelines § 2B1.1.
The maximum penalty is five years in federal prison per violation, meaning multiple false claims can result in consecutive sentences.
If fraud exceeds $1.5 million, sentence enhancements apply. Defendants who used forged documents, engaged in extensive planning, or involved co-conspirators may receive harsher sentences under the sophisticated means enhancement.
Why TRICARE Compounding Pharmacy Cases Draw Federal Attention
Historically, TRICARE's reimbursement structure paid compounded medications at ingredient cost, without the caps that govern commercial insurance.
Defendants in documented federal cases manipulated compound formulas to ensure the highest possible reimbursement from TRICARE, generating tens of millions of dollars in reimbursements in a matter of months.
That structural vulnerability made TRICARE the primary target for compounding fraud schemes throughout the 2012 to 2016 period and beyond.
Federal prosecutors have described the pattern as systemic fraud against TRICARE.
Marketing companies cold-call TRICARE beneficiaries and pitch compound creams, collecting TRICARE information and the beneficiary's physician's name to generate a prescription, often without a prior office visit.
Pharmacies then bill TRICARE at maximum reimbursement, with kickbacks flowing back to marketers and prescribing physicians through arrangements disguised as research fees, speaker fees, or percentage-based referral payments.
How Federal Investigators Build These Cases
Investigations to identify alleged fraud and abuse under the False Claims Act and Anti-Kickback Statute involve data mining to identify increases in prescriptions for a particular compounding drug when a commercially available drug serves the same purpose, as well as identifying physicians who prescribe high amounts of pain creams, scar creams, and wrinkle creams.
When a pharmacy's billing volume or prescription concentration deviates from regional norms, it generates a flag that can trigger subpoenas, grand jury proceedings, and ultimately an indictment.
Several federal agencies coordinate these investigations, including the FBI, HHS-OIG, and the DCIS. Once the investigation is underway, it can unravel the full structure of a pharmacy's marketing and prescribing relationships.
By the time agents make initial contact, they typically possess pharmacy billing records, financial institution records, prescriber data, and communications obtained through subpoena. Former employees frequently surface as cooperating witnesses.
The Statute Cluster Prosecutors Use
Prosecutors do not limit these cases to § 287 alone. The statutes most commonly charged alongside false claims in compounding pharmacy prosecutions create a layered exposure that considerably multiplies the sentencing risk, such as the following:
- The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) carries a penalty of up to 10 years per violation and applies to any knowing and willful payment of remuneration to induce or reward referrals.
- 18 U.S.C. § 1347 for health care fraud adds up to ten years per count on top of the § 287 exposure.
- 18 U.S.C. § 1349 conspiracy charges carry the same maximum as the underlying offense,
- 18 U.S.C. § 1956 money laundering adds up to twenty years per count when proceeds were transferred or concealed.
The Eliminating Kickbacks in Recovery Act (EKRA, 18 U.S.C. § 220) applies to kickback payments for referrals to pharmacies, including compounding pharmacies, covers all payors, including TRICARE and private insurance, and carries penalties of up to ten years and $200,000 per violation, with narrower safe harbors than the Anti-Kickback Statute.
Commission-based compensation to sales personnel violates EKRA even if permissible under the AKS. Forfeiture and restitution run separately from all of these, and in large-scale TRICARE cases, forfeiture orders have exceeded nine figures.
Why These Related Laws Matter
Investigations into TRICARE fraud in compounding pharmacies seldom rely on a single charge.
What starts as an allegation under 18 U.S.C. § 287 frequently develops into a comprehensive federal case, encompassing charges like health care fraud, conspiracy, kickbacks, EKRA violations, money laundering, forfeiture proceedings, and civil False Claims Act claims.
Since each added charge can greatly raise the potential sentence, pharmacy owners and healthcare professionals should develop a coordinated federal defense strategy early in an investigation.
Frequently Asked Questions (FAQs)
Can a compounding pharmacy owner be charged with TRICARE fraud even if they did not submit claims personally?
Yes. Federal prosecutors frequently target owners, executives, pharmacists, marketers, and other involved parties suspected of knowing about or benefiting from a fraudulent billing scheme. Under federal conspiracy and aiding-and-abetting laws, someone can be criminally liable even without directly making a claim.
What is the difference between a False Claims Act case and a criminal prosecution under 18 U.S.C. § 287?
The False Claims Act is a civil law enabling the government to seek damages and penalties for submitting false claims to federal programs.
Conversely, 18 U.S.C. § 287 is a criminal law that can result in federal prison time, fines, restitution, and other penalties. In numerous TRICARE fraud cases, defendants often face both civil and criminal consequences.
How do federal investigators identify potential TRICARE fraud schemes?
Federal agencies frequently analyze billing data, prescription records, financial documents, and whistleblower reports to detect anomalies.
Investigators often target pharmacies with suspiciously high reimbursements, a large number of compound cream prescriptions, dubious referral partnerships, or payments to marketers and prescribers.
Can I be prosecuted if I relied on a marketing company or consultant?
Possibly. However, relying on third-party marketers, consultants, or business advisors may support your defense if you were unaware that the arrangement infringed federal law.
A central question in many cases is whether the government can demonstrate that you knowingly engaged in a fraudulent or illegal kickback scheme.
What should I do if I receive a federal subpoena related to a TRICARE investigation?
You should consult an experienced federal criminal defense attorney right away before speaking to investigators or handing over documents.
Acting early with legal counsel can safeguard your rights, maintain critical defenses, and possibly shape the course of the investigation before formal charges are filed.
Defense Strategies That Work
Attacking the Knowledge and Intent Element
The government has to demonstrate that the defendant intentionally submitted a false claim. Defending against false claims charges involves careful examination of intent, relevant documentation, and adherence to compliance procedures.
A pharmacy owner who depended on third-party marketing, filled prescriptions from licensed physicians, and was unaware that these prescriptions were obtained through kickback schemes is in a significantly different legal situation than someone who created the scheme.
The owner's knowledge, timing, and existing compliance infrastructure are often the most critical factors in the case.
Isolating the Kickback Relationship
Every prescription submitted through a kickback arrangement constitutes a false claim, and each false claim carries penalties per count. But establishing that a payment arrangement constituted an illegal kickback requires proving remuneration was given specifically to induce referrals.
Flat-fee arrangements, bona fide service contracts with marketing firms, and payments that fit within recognized safe harbors under the Anti-Kickback Statute can all be analyzed as legitimate business conduct rather than criminal inducement.
Challenging the Government's Loss Calculation
Federal sentencing in these cases turns substantially on the loss figure. Prosecutors calculate loss as the full amount billed to TRICARE, without credit for the actual value of medications dispensed.
Defense challenges to that methodology, including arguments that legitimately compounded medications provided real therapeutic value and that only the improperly billed portion constitutes criminal loss, can meaningfully reduce the guidelines range and the sentencing outcome.
Engaging Before Indictment
The period between initial federal contact and a formal indictment is the most consequential window for defense intervention.
During the prefiling stage, federal criminal defense attorneys can negotiate with the federal prosecutor to reach a resolution before indictment, which could reduce penalties.
Presenting a compliance narrative, demonstrating remediation steps already taken, and drawing a clear factual boundary around the owner's actual knowledge can each influence whether charges are filed, and on what terms.
Compounding Pharmacy Owner Avoids Indictment Through Prefiling Engagement
A compounding pharmacy owner in the Southeast received a Defense Criminal Investigative Service subpoena requesting two years of TRICARE billing records, marketing contracts, and prescriber correspondence.
The pharmacy had been working with an independent marketing company that provided patient referrals in exchange for a percentage-based fee.
The owner had not structured the arrangement and was not aware that similar contracts at other pharmacies had already resulted in indictments.
Defense counsel was retained before any documents were produced and before any interview was given. Counsel conducted a comprehensive review of the marketing contracts and found that the fee structure, while potentially implicating EKRA, had not been established with the pharmacy owner's knowledge of its illegality.
The owner had sought general business advice from a consultant before signing the contract, but had not received legal review.
Counsel submitted a detailed factual and legal memorandum to the assigned DOJ prosecutor identifying the absence of fraudulent intent, the owner's reliance on a third-party contractor structure, and the pharmacy's compliance history with state board requirements.
The memorandum also disclosed that the marketing contract had been terminated upon receipt of the subpoena and that the pharmacy had self-audited its TRICARE claims.
The DOJ resolved the matter civilly rather than criminally. The pharmacy paid a settlement under the civil False Claims Act, retained its DEA registration, and the owner was not charged under § 287 or the Anti-Kickback Statute.
The resolution preserved both the business and the owner's ability to continue operating. Contact the attorneys at Eisner Gorin LLP today for a free consultation.